News

Show
news from

Autolus Therapeutics to Present Four Clinical Data Updates at the European Hematology Association Congress

Achilles Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights

Neogene Therapeutics Announces Approval of Clinical Trial Application for its First Phase 1 Trial of Novel, Fully-Individualized TCR Therapy to Treat Advanced Solid Tumors

Achilles Therapeutics Doses First Patient with Higher-dose cNeT in Phase I/IIa CHIRON Trial in Advanced NSCLC and Initiates Enrollment in Cohort B of the THETIS Trial (cNeT + PD-1 checkpoint inhibitor) in Metastatic Malignant Melanoma

Autolus Therapeutics Reports First Quarter 2022 Financial Results and Operational Progress

Achilles Therapeutics Appoints Bernhard Ehmer to Board of Directors

Load more

Search